Clinical trials: Diabetes, Type II
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01006291)
- Testing
- insulin degludec, insulin glargine
- Where
- 72 sites in Argentina, Finland and 12 more
- Volunteers
- 687 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.
- Trial name
- NCT01131182
- Testing
- Sitagliptin phosphate, Comparator: Sulfonylurea, Metformin
- Volunteers
- 1,147 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes
This study assessed the safety, pharmacokinetics and efficacy of bimagrumab when administered in overweight and obese patients with type 2 diabetes
- Trial name
- NCT03005288
- Testing
- BYM338 10 mg/kg
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 78 people
- Sponsor
- Novartis Pharmaceuticals
Type II Diabetes, Primary Health Care
INTEGRATE-D: A Pilot Test to Support Integration of Medical and Psychosocial Care for People With Type II Diabetes
In 2016, the American Diabetes Association (ADA) published its first-ever recommendations for integrating medical and psychosocial care for patients with Type II Diabetes Mellitus (DMII) and common mental and behavioral health…
- Conditions
- Type II Diabetes, Primary Health Care, Behavioral Health
- Trial name
- NCT04461405
- Testing
- INTEGRATE-D
- Where
- United States
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Diabetes Mellitus, Type 2
Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
This is a prospective, non-interventional, open label, multi center, post marketing surveillance study designed to assess the safety, tolerability and efficacy of Linagliptin among Filipino patients with type 2 Diabetes Mellitus…
- Trial name
- NCT01826370
- Testing
- Linagliptin
- Where
- 51 sites in Philippines
- Volunteers
- 678 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Japanese P III vs Voglibose and Placebo
The objective of the current study is to investigate the efficacy, safety and tolerability of Linagliptin (BI 1356) (5 mg or 10 mg / once daily) compared to placebo given for 12 weeks and voglibose for 26 weeks as mono therapy in…
- Trial name
- NCT00654381
- Testing
- BI 1356, voglibose
- Where
- 47 sites in Japan
- Volunteers
- 561 people
- Sponsor
- Boehringer Ingelheim
Diabetes
Phase III Insulin Add-On Asia Regional Program - ST
The purpose is to determine if after 24 weeks of oral daily administration, there will be a greater mean reduction from baseline in glycosylated hemoglobin (HbA1c) achieved with Dapagliflozin 10 mg plus insulin compared to…
- Trial name
- NCT02096705
- Testing
- Dapagliflozin
- Where
- 29 sites in China, Singapore and 1 more
- Volunteers
- 477 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study for Participants With Type 2 Diabetes Mellitus
This drug is being evaluated for possible treatment of type 2 diabetes mellitus. Participation in this study is expected to last up to 18 weeks. A goal of this study is to determine the safety and effectiveness of LY2409021.
- Trial name
- NCT00871572
- Testing
- LY2409021
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus.
- Trial name
- NCT02121483
- Testing
- empagliflozin medium dose, empagliflozin high dose, empagliflozin low dose
- Where
- 11 sites in United States, France and 3 more
- Volunteers
- 27 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (5 mg once daily) compared to placebo given for 24 weeks as add-on therapy to metformin in combination with a sulphonylurea in…
- Trial name
- NCT00602472
- Testing
- linagliptin
- Where
- 100 sites in Argentina, Belgium and 9 more
- Volunteers
- 1,058 people
- Sponsor
- Boehringer Ingelheim
Diabetes Type 2
The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes
The purpose of this research is to study and determine the effects of Aliskiren on blood vessels and blood flow. The primary hypothesis is that Aliskiren will increase endothelial function by 30% or more in comparison to the…
- Trial name
- NCT01165983
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Type 2 Diabetes Mellitus
A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)
A study to compare safety and efficacy of sitagliptin and placebo therapy when added to stable insulin alone or in combination with metformin in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01590797
- Testing
- Sitagliptin, Insulin, Metformin
- Volunteers
- 467 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use
The purpose of this study is to demonstrate the performance of the Enlite Sensor over an entire calibration and wear period of 146 hours (6 days) when inserted in the abdomen and buttock and used with the Revel 2.0 Pumps in…
- Trial name
- NCT01464346
- Testing
- Enlite Sensor
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Related Complications
QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia
Hypoglycaemia is the most common acute complication of diabetes and can limit therapeutic efforts to improve glycaemic control. It is a potential side effect of drugs used to treat diabetes, particularly with the use of…
- Trial name
- NCT02298803
- Testing
- Holter and Glucose monitoring
- Volunteers
- 30 people
- Sponsor
- Royal Prince Alfred Hospital, Sydney, Australia
Type 2 Diabetes Mellitus
A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)
This study will compare the benefits of exenatide once weekly treatment to those achieved by the approved antidiabetic therapies sitagliptin and pioglitazone in subjects whose type 2 diabetes is managed with metformin therapy…
- Trial name
- NCT00637273
- Testing
- exenatide once weekly, sitagliptin, pioglitazone
- Where
- 62 sites in United States, India and 1 more
- Volunteers
- 514 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes
Fast-acting insulin aspart (faster aspart) will be tested to see how well it works and if it is safe. The study compares 2 medicines for type 1 and type 2 diabetes - faster aspart (a new medicine) and insulin aspart (a medicine…
- Trial name
- NCT04588259
- Testing
- Faster aspart, Insulin aspart, Insulin degludec
- Where
- 40 sites in China, Hong Kong
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
COVID-19
Impact of COVID-19 on Marshallese Communities in the U.S.
Marshallese adults in the U.S. will complete an online or telephone survey. This survey will collect data describing the impact of COVID-19 on Marshallese communities.
- Trial name
- NCT04474496
- Testing
- Assessing the impact of COVID-19
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Arkansas
Diabetes Mellitus, Type 2
Effects of Qigong on Type 2 Diabetic Patients
Qigong therapy is a subtle energy-based methodology for preventing and healing diseases that has been practiced with remarkable results in China for about five thousand years.
- Trial name
- NCT00885846
- Testing
- Qigong therapy, Progressive resistance training
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Bastyr University
Type 2 Diabetes
Social Support Intervention for Older Adults With T2DM
This study seeks to describe and evaluate the impact of social support on self-care and clinical outcomes in rural-dwelling older adults with T2DM, test the feasibility and preliminary effectiveness of a 6-week intervention…
- Trial name
- NCT04568486
- Testing
- Diabetes Empowerment Education Program
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Brittany L Smalls
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign
This program will provide patients with type 1 and high risk type 2 diabetes the safest hospitalization by using wireless continuous glucose monitoring devices (CGM) to track their glucose parameters in real-time similar to other…
- Trial name
- CGM (NCT03068273)
- Testing
- Real-time CGM data
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Scripps Whittier Diabetes Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.